261 related articles for article (PubMed ID: 31075537)
21. Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.
Blakely CM; Riess JW
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1061-1075. PubMed ID: 31809604
[No Abstract] [Full Text] [Related]
22. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Soria JC; Tan DSW; Chiari R; Wu YL; Paz-Ares L; Wolf J; Geater SL; Orlov S; Cortinovis D; Yu CJ; Hochmair M; Cortot AB; Tsai CM; Moro-Sibilot D; Campelo RG; McCulloch T; Sen P; Dugan M; Pantano S; Branle F; Massacesi C; de Castro G
Lancet; 2017 Mar; 389(10072):917-929. PubMed ID: 28126333
[TBL] [Abstract][Full Text] [Related]
23. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis.
Cho BC; Kim DW; Batra U; Park K; Kim SW; Yang CT; Voon PJ; Sriuranpong V; Babu KG; Amin K; Wang Y; Sen P; Slimane K; Geater S
Cancer Res Treat; 2023 Jan; 55(1):83-93. PubMed ID: 35344649
[TBL] [Abstract][Full Text] [Related]
25. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT
J Clin Oncol; 2016 Aug; 34(24):2866-73. PubMed ID: 27432917
[TBL] [Abstract][Full Text] [Related]
26. Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
Won B; Mambetsariev I; Salgia R
BMC Cancer; 2016 Aug; 16():568. PubMed ID: 27480287
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
[TBL] [Abstract][Full Text] [Related]
28. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
30. ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
Chow LQM; Barlesi F; Bertino EM; van den Bent MJ; Wakelee HA; Wen PY; Chiu CH; Orlov S; Chiari R; Majem M; McKeage M; Yu CJ; Garrido P; Hurtado FK; Arratia PC; Song Y; Branle F; Shi M; Kim DW
Clin Cancer Res; 2022 Jun; 28(12):2506-2516. PubMed ID: 35091443
[TBL] [Abstract][Full Text] [Related]
31. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N
J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
[TBL] [Abstract][Full Text] [Related]
32. Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
Wu YL; Shi Y; Tan DSW; Xiaoqing L; Cheng Y; Zhou J; An TT; Lu Y; Zhu B; Bai C; Passos VQ; Lau YY; Xun L; Zhang L
Lung Cancer; 2020 Dec; 150():240-246. PubMed ID: 33249379
[TBL] [Abstract][Full Text] [Related]
33. Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
Metro G; Passaro A; Lo Russo G; Bonanno L; Giusti R; Gregorc V; Capelletto E; Martelli O; Cecere FL; Giannarelli D; Luciani A; Bearz A; Tuzi A; Scotti V; Tonini G; Galetta D; Carta A; Soto Parra H; Rebonato A; Morabito A; Chiari R
Future Oncol; 2018 Feb; 14(4):353-361. PubMed ID: 29135281
[TBL] [Abstract][Full Text] [Related]
34. Ceritinib Bests Chemo for Untreated ALK
Cancer Discov; 2017 Apr; 7(4):OF6. PubMed ID: 28193771
[TBL] [Abstract][Full Text] [Related]
35. Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
Vansteenkiste JF
Future Oncol; 2014 Oct; 10(12):1925-39. PubMed ID: 24856155
[TBL] [Abstract][Full Text] [Related]
36. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
Fischer M; Moreno L; Ziegler DS; Marshall LV; Zwaan CM; Irwin MS; Casanova M; Sabado C; Wulff B; Stegert M; Wang L; Hurtado FK; Branle F; Geoerger B; Schulte JH
Lancet Oncol; 2021 Dec; 22(12):1764-1776. PubMed ID: 34780709
[TBL] [Abstract][Full Text] [Related]
37. Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.
Santoro A; Su WC; Navarro A; Simonelli M; Ch Yang J; Ardizzoni A; Barlesi F; Hyoung Kang J; DiDominick S; Abdelhady A; Chen X; Stammberger U; Felip E
Lung Cancer; 2022 Apr; 166():170-177. PubMed ID: 35298959
[TBL] [Abstract][Full Text] [Related]
38. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
[No Abstract] [Full Text] [Related]
39. Application of time-dependent modeling for the exposure-efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients.
Lau YY; Gu W; Ho YY; Hong Y; Zhang X; Urban P
Cancer Chemother Pharmacol; 2019 Sep; 84(3):501-511. PubMed ID: 31020351
[TBL] [Abstract][Full Text] [Related]
40. Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer.
Cooper MR; Chim H; Chan H; Durand C
Ann Pharmacother; 2015 Jan; 49(1):107-12. PubMed ID: 25258420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
